• News
  • SAN DIEGO
  • BioTech

Anti-obesity drugs show their stuff on Wall Street

Local rivals Arena and Orexigen to speak to investors

As one of Wall Street’s top biotech conferences gets under way in New York today, two key companies to watch will be San Diego’s Arena Pharmaceuticals Inc. and Orexigen Therapeutics Inc., says biotech reporter Brett Chase, writing in the investment analysis website Minyanville.

Investment fund managers will be hearing from more than 100 companies at the Bio CEO & Investor Conference, sponsored by the Biotechnology Industry Association. Chase says one of the six hottest topics at the conference is the race to bring new anti-obesity pills to the market.

Arena (Nasdaq: ARNA) is waiting for the Food and Drug Administration to give a green light for its approved drug Belviq to go on sale. Orexigen (Nasdaq: OREX) hopes to apply for approval for its drug Contrave this summer or fall. Vivus Inc. (Nasdaq: VVUS), based near Silicon Valley, launched a drug called Qsymia last September, but sales have been so slow that some major stockholders have called for the company to be sold.

Orexigen and Arena are slated to make presentations at Bio CEO Tuesday afternoon and the Leerink Swann Global Healthcare Conference on Wednesday morning.

RELATED ARTICLES:

Arena slumps on continued concerns for Belviq

FDA clears two Life Technologies products

Regen BioPharma files FDA application for anemia drug

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!